Makers Labs.

Which are the latest news on Makers Labs.?

Why is Makers Laboratories Ltd falling/rising?

As of 13-Jun, the stock price of Makers Laboratories Ltd is rising to 156.85, reflecting a 10.46% increase. This rise is supported by strong relative performance, trading above key moving averages, and positive market sentiment, despite a decline in investor participation.

As of 13-Jun, the stock price of Makers Laboratories Ltd is rising, currently at 156.85, which reflects an increase of 14.85 or 10.46%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 10.64% today, indicating strong relative performance. It opened with a gain of 2.71% and reached an intraday high of Rs 158.85, marking an increase of 11.87%. <BR><BR>Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish signal. Over the past week, the stock has shown a positive return of 7.73%, significantly outperforming the Sensex, which only gained 1.73%. <BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 36.05% compared to the 5-day average. Despite this decrease in participation, the overall performance metrics and the stock's ability to maintain higher trading levels suggest that the price is rising due to positive market sentiment and strong short-term performance.

How big is Makers Labs.?

As of 10th June, Makers Laboratories Ltd has a market capitalization of 86.00 Cr, with recent net sales of 140.59 Cr and a net profit of 2.35 Cr. Shareholder's funds are 70.51 Cr, and total assets amount to 147.95 Cr.

As of 10th June, Makers Laboratories Ltd has a market capitalization of 86.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 140.59 Cr and a Net Profit of 2.35 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 70.51 Cr and Total Assets of 147.95 Cr.

Who are in the management team of Makers Labs.?

The management team of Makers Labs includes R K P Verma (Chairman), Dipti Shah, Vishal Jain (Independent Directors), Prashant Godha (Non-Executive Director), Saahil U Parikh, Nilesh Jain (Executive Directors), and Surbhi Sharma (Company Secretary).

The management team of Makers Labs includes the following individuals:<BR><BR>1. R K P Verma - Chairman & Independent Director<BR>2. Dipti Shah - Independent Non-Executive Director<BR>3. Vishal Jain - Independent Non-Executive Director<BR>4. Prashant Godha - Non-Executive & Non-Independent Director<BR>5. Saahil U Parikh - Non-Independent Executive Director<BR>6. Nilesh Jain - Non-Independent Executive Director<BR>7. Surbhi Sharma - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Makers Labs.?

Makers Labs. peers include Pharmaids Pharma, Denis Chem Lab, Mercury Labs, Amwill Health, Bharat Immunolog, Bacil Pharma, Onyx Biotec, Vaishali Pharma, and Vilin Bio Med. In terms of management risk, growth, and capital structure, Denis Chem Lab and Amwill Health perform excellently, while Makers Labs. and several peers show below-average performance.

Peers: The peers of Makers Labs. are Pharmaids Pharma, Denis Chem Lab, Mercury Labs, Amwill Health, Bharat Immunolog, Bacil Pharma, Onyx Biotec, Vaishali Pharma, and Vilin Bio Med.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab and Amwill Health, while Average management risk is found at Mercury Labs and Onyx Biotec. Below Average management risk is noted for Pharmaids Pharma, Makers Labs., Bharat Immunolog, Vaishali Pharma, and Vilin Bio Med, and Bacil Pharma does not qualify. Growth is Excellent at Denis Chem Lab and Amwill Health, Average at Onyx Biotec, and Below Average at Pharmaids Pharma, Mercury Labs, Makers Labs., Bharat Immunolog, Vaishali Pharma, and Vilin Bio Med, with Bacil Pharma not qualifying. Capital Structure is Excellent at Denis Chem Lab and Amwill Health, Average at Onyx Biotec, and Below Average at Pharmaids Pharma, Mercury Labs, Makers Labs., Bharat Immunolog, Vaishali Pharma, and Vilin Bio Med, while Bacil Pharma does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bacil Pharma at 23.76%, while the lowest is Pharmaids Pharma at -52.99%. Makers Labs. has a 1-year return of -7.55%, which is higher than Pharmaids Pharma but lower than Bacil Pharma. Additionally, the six-month return is negative for Pharmaids Pharma, Bharat Immunolog, and Vilin Bio Med.

What does Makers Labs. do?

Makers Laboratories Ltd manufactures pharmaceutical formulations and drug intermediates, classified as a Micro Cap company. As of March 2026, it reported net sales of 36 Cr and a net profit of 1 Cr, with a market cap of INR 86 Cr.

Overview: <BR>Makers Laboratories Ltd is engaged in the manufacture of pharmaceutical formulations and drug intermediates, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Makers Laboratories Ltd was incorporated in 1984 and commenced business on 21st July of that year. The company underwent a status change with the amalgamation of Makers Drugs & Food Products Ltd. on 1st April 1993. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 36 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 86 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.08 <BR>Return on Equity: 3.22% <BR>Price to Book: 1.15 <BR><BR>Contact Details: <BR>Address: 54 D Kandivli Industrial Estate, Charkop Kandivli (West) Mumbai Maharashtra: 400067 <BR>Tel: 91-22-2868 8544 <BR>Email: investors@makerslabs.com <BR>Website: http://www.makerslabs.com

Should I buy, sell or hold Makers Laboratories Ltd?

Are Makers Laboratories Ltd latest results good or bad?

Makers Laboratories Ltd's latest results show a mixed performance, with a 15.96% increase in net profit and improved operating margins, but concerns remain due to a negative return on equity, declining EBIT growth, and high valuation compared to industry averages. Overall, caution is advised for investors given the underlying challenges.

Makers Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹1.09 crores for Q4 FY26, which is a 15.96% increase quarter-on-quarter. Additionally, net sales reached ₹35.75 crores, reflecting a 5.46% year-on-year growth, and the operating margin improved to 14.74%, the highest in seven quarters. These metrics indicate some positive operational improvements and margin expansion.<BR><BR>However, there are significant concerns that temper this optimism. The return on equity (ROE) is currently at -0.02%, indicating that the company is in negative territory regarding shareholder value creation. Furthermore, the five-year EBIT growth stands at -15.78%, suggesting fundamental weaknesses in the business. The disparity between standalone profit of ₹3.56 crores and consolidated profit of ₹1.09 crores raises questions about the performance of its subsidiaries.<BR><BR>The company's high price-to-earnings ratio of 79.74 times, significantly above the pharmaceutical sector average of 34 times, raises valuation concerns, especially given its below-average quality rating and lack of institutional ownership. <BR><BR>In summary, while there are some positive signs in the recent quarterly performance, the underlying challenges and historical performance issues suggest a cautious outlook for investors.

Is Makers Labs. overvalued or undervalued?

As of November 10, 2025, Makers Labs. is considered overvalued with a PE ratio of -4693.22, unfavorable comparisons to peers like Sun Pharma and Cipla, and a significant year-to-date stock decline of 34% versus the Sensex's gain of 6.91%.

As of 10 November 2025, the valuation grade for Makers Labs. has moved from very attractive to very expensive. This indicates a significant shift in the company's perceived value, suggesting that it is currently overvalued. The company's PE ratio stands at an alarming -4693.22, while its EV to EBITDA is 8.94 and EV to Sales is 0.66, which are concerning figures in the context of its financial health.<BR><BR>In comparison to its peers, Makers Labs. is positioned unfavorably against companies like Sun Pharma. Inds., which has a PE ratio of 35.15 and an EV to EBITDA of 10.64, and Cipla, which boasts a PE ratio of 22.45 and an EV to EBITDA of 5.67. The stark contrast in these ratios highlights the overvaluation of Makers Labs. Furthermore, the company's stock has underperformed the Sensex significantly over various periods, with a year-to-date decline of 34.00% compared to the Sensex's gain of 6.91%. Overall, the evidence strongly supports that Makers Labs. is overvalued in the current market.

How has been the historical performance of Makers Labs.?

Makers Labs has shown fluctuating performance over the past five years, with net sales increasing to 120.75 Cr in March 2025, and a significant recovery in profitability, reporting a profit after tax of 10.91 Cr. However, the company faces challenges with negative cash flow of -4.00 Cr in March 2025.

Answer:<BR>The historical performance of Makers Labs shows a fluctuating trend in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Makers Labs reported net sales of 120.75 Cr in March 2025, an increase from 104.39 Cr in March 2024 and 101.28 Cr in March 2023, but a decline from 126.63 Cr in March 2022. The total operating income mirrored this trend, reaching 120.75 Cr in March 2025. The company's total expenditure, excluding depreciation, was 112.36 Cr in March 2025, up from 103.34 Cr in March 2024, leading to an operating profit (PBDIT) of 8.39 Cr, a significant recovery from 1.05 Cr in the previous year. However, the operating profit margin (excluding other income) was 6.95% in March 2025, compared to 1.01% in March 2024. Profit before tax improved to 13.41 Cr in March 2025, recovering from a loss of 3.92 Cr in March 2024, while profit after tax was 10.91 Cr, a turnaround from a loss of 4.81 Cr the previous year. The consolidated net profit for March 2025 was 7.49 Cr, compared to a loss of 6.26 Cr in March 2024. The company's total assets decreased to 147.95 Cr in March 2025 from 161.26 Cr in March 2024, and total liabilities also fell to 147.95 Cr from 161.26 Cr. Cash flow from operating activities was negative at -4.00 Cr in March 2025, contrasting with a positive cash flow of 0.00 Cr in March 2024. Overall, while Makers Labs has shown signs of recovery in sales and profitability, it continues to face challenges in cash flow management.

Who are the top shareholders of the Makers Labs.?

The top shareholder of Makers Labs is Kaygee Investments Private Limited with a 17.38% stake, followed by public shareholder Tanvi Jignesh Mehta at 2.18%. Individual investors own 31.01% of the company, with no mutual funds or foreign institutional investors currently holding shares.

The top shareholders of Makers Labs include Kaygee Investments Private Limited, which holds the highest stake at 17.38%. The majority of the shares are held by promoters, and there are no pledged promoter holdings. In terms of public shareholders, Tanvi Jignesh Mehta is the largest, holding 2.18%. Additionally, individual investors collectively own 31.01% of the company. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in Makers Labs.

What is the technical trend for Makers Labs.?

As of June 5, 2025, Makers Labs shows a mildly bullish trend primarily supported by the weekly MACD and Bollinger Bands, despite some caution from daily moving averages and no clear signals from the RSI or Dow Theory.

As of 5 June 2025, the technical trend for Makers Labs has changed from sideways to mildly bullish. The weekly MACD is mildly bullish, supported by a bullish stance in both the weekly and monthly Bollinger Bands. The KST also indicates a mildly bullish trend on the weekly and bullish on the monthly. However, the daily moving averages are mildly bearish, which adds some caution to the overall outlook. The RSI shows no signal on both weekly and monthly time frames, and Dow Theory indicates no trend in either time frame. Overall, the current stance is mildly bullish, driven primarily by the MACD and Bollinger Bands.

When is the next results date for Makers Labs.?

No Upcoming Board Meetings

Has Makers Labs. declared dividend?

Makers Laboratories Ltd has declared a 10% dividend, amounting to 1 per share, but the dividend yield is 0%. While the company has shown significant price returns over various periods, dividends have not contributed to overall returns recently.

Makers Laboratories Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1<BR>- Ex-date: 01 Aug 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -1.64%, the dividend return was 0%, resulting in a total return of -1.64%.<BR><BR>For the 1-year period, the price return was 40.63%, the dividend return was 0%, leading to a total return of 40.63%.<BR><BR>Over the 2-year period, the price return was 54.5%, with a dividend return of 0%, culminating in a total return of 54.5%.<BR><BR>In the 3-year period, the price return was 10.17%, the dividend return was 0%, resulting in a total return of 10.17%.<BR><BR>During the 4-year period, the price return was -29.09%, with a dividend return of 0%, leading to a total return of -29.09%.<BR><BR>For the 5-year period, the price return was 292.08%, the dividend return was 0%, resulting in a total return of 292.08%.<BR><BR>Overall, while Makers Laboratories Ltd has declared a dividend, the dividend yield remains at 0%, indicating that dividends have not contributed to returns in recent periods. The total returns show significant variability, with particularly strong performance over the 5-year period.